Get the Stockscreener App
0.619
1.98%
0.012
Pre-market:
.63
0.011
+1.78%
AEON Biopharma Inc. stock is traded at $0.619, with a volume of 1.00M.
It is up +1.98% in the last 24 hours and up +47.38% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$0.607
Open:
$0.6037
24h Volume:
1.00M
Relative Volume:
0.31
Market Cap:
$7.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+27.37%
1M Performance:
+47.38%
6M Performance:
-98.39%
1Y Performance:
-99.38%
1-Day Range:
$0.5889
$0.64
1-Week Range:
$0.48
$0.8481
52-Week Range:
$0.375
$269.28
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.619 | 5.49M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
Aeon Biopharma Reports Positive Q1 2025 Earnings - TipRanks
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 - The Manila Times
AEON Biopharma to Present Corporate Overview at Aegis Capital Corp. 2025 Virtual Conference - Nasdaq
AEON Biopharma Unveils Next-Gen Botulinum Toxin Therapies: CEO Details Multi-Indication Pipeline - Stock Titan
AEON Biopharma Advances Biosimilar Product Development and Appoints New CEO - Nasdaq
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
New AEON CEO Targets $3.3B Botox Market with FDA-Ready Biosimilar Development Plan - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Tuesday - Defense World
Closing Bell Recap: AEON Biopharma Inc (AEON) Ends at 0.75, Reflecting a -11.76 Downturn - DWinneX
AEON Biopharma Inc (AMEX: AEON) Stock: Investors Need To Know This - Stocksregister
Is AEON Biopharma Inc’s (AMEX:AEON) Stock On The Decline? - Stocksregister
AEON Biopharma gets NYSE American nod for compliance plan - Investing.com Australia
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
AEON Biopharma gets NYSE American nod for compliance plan By Investing.com - Investing.com India
AEON Biopharma Says NYSE American Accepts Plan to Regain Compliance - marketscreener.com
AEON Biopharma Receives Acceptance from NYSE American to Regain Compliance with Listing Standards - Nasdaq
NYSE American Grants AEON Biopharma 2-Year Lifeline to Meet Listing Requirements - Stock Titan
What was AEON Biopharma Inc (AEON)’s performance in the last session? - uspostnews.com
Analyzing the Impact of Earnings Reports on AEON Biopharma Inc Inc. (AEON) Price Performance - investchronicle.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
AEON Biopharma, Inc. Announces Executive Changes, Effective as of April 4, 2025 - marketscreener.com
AEON Biopharma announces CEO appointment - MSN
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer - The Manila Times
AEON Biopharma names Rob Bancroft as new CEO By Investing.com - Investing.com South Africa
Aeon Biopharma Names Robert Bancroft CEO - marketscreener.com
AEON Biopharma Appoints New CEO Robert Bancroft - TipRanks
Aeon Biopharma (AEON) Appoints Rob Bancroft as New CEO | AEON Stock News - GuruFocus
AEON Biopharma Appoints Rob Bancroft as CEO - MarketWatch
AEON Biopharma names Rob Bancroft as new CEO - Investing.com
AEON Biopharma (NASDAQ:AEON) Trading 2.5% Higher – Time to Buy? - Defense World
AEON Biopharma announces new interim CEO and CFO By Investing.com - Investing.com Australia
AEON Biopharma Appoints Jost Fischer as Interim CEO - TipRanks
AEON Biopharma announces new interim CEO and CFO - Investing.com
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
AEON Biopharma Inc (AEON) Stock: The Story of a 52-Week Stock Range - investchronicle.com
AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1 - NewsBreak: Local News & Alerts
AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines
Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal
AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener
AEON Biopharma announces leadership change amid growth strategy - Investing.com
AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks
AEON Biopharma Announces CEO Transition - The Manila Times
Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan
AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025 - insights.citeline.com
AEON Biopharma Inc. Stock (AEON) Financials Data
There is no financial data for AEON Biopharma Inc. (AEON). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
8.70%
1.64%
Cap:
|
Volume (24h):